Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer

A systematic review

Primož Strojan, Jan B. Vermorken, Jonathan J. Beitler, Nabil F. Saba, Missak Haigentz, Paolo Bossi, Francis P. Worden, Johannes A. Langendijk, Avraham Eisbruch, William M. Mendenhall, Anne W M Lee, Louis B. Harrison, Carol R. Bradford, Robert Smee, Carl E. Silver, Alessandra Rinaldo, Alfio Ferlito

Research output: Contribution to journalReview article

51 Citations (Scopus)

Abstract

Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

Original languageEnglish (US)
Pages (from-to)E2151-E2158
JournalHead and Neck
Volume38
DOIs
StatePublished - Apr 1 2016

Fingerprint

Chemoradiotherapy
Head and Neck Neoplasms
Cisplatin
Survival
Radiotherapy
Appointments and Schedules
Outcome Assessment (Health Care)
Carcinoma, squamous cell of head and neck

Keywords

  • cisplatin
  • concurrent chemoradiotherapy
  • cumulative dose
  • outcome
  • radiotherapy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Strojan, P., Vermorken, J. B., Beitler, J. J., Saba, N. F., Haigentz, M., Bossi, P., ... Ferlito, A. (2016). Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head and Neck, 38, E2151-E2158. https://doi.org/10.1002/hed.24026

Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer : A systematic review. / Strojan, Primož; Vermorken, Jan B.; Beitler, Jonathan J.; Saba, Nabil F.; Haigentz, Missak; Bossi, Paolo; Worden, Francis P.; Langendijk, Johannes A.; Eisbruch, Avraham; Mendenhall, William M.; Lee, Anne W M; Harrison, Louis B.; Bradford, Carol R.; Smee, Robert; Silver, Carl E.; Rinaldo, Alessandra; Ferlito, Alfio.

In: Head and Neck, Vol. 38, 01.04.2016, p. E2151-E2158.

Research output: Contribution to journalReview article

Strojan, P, Vermorken, JB, Beitler, JJ, Saba, NF, Haigentz, M, Bossi, P, Worden, FP, Langendijk, JA, Eisbruch, A, Mendenhall, WM, Lee, AWM, Harrison, LB, Bradford, CR, Smee, R, Silver, CE, Rinaldo, A & Ferlito, A 2016, 'Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review', Head and Neck, vol. 38, pp. E2151-E2158. https://doi.org/10.1002/hed.24026
Strojan P, Vermorken JB, Beitler JJ, Saba NF, Haigentz M, Bossi P et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review. Head and Neck. 2016 Apr 1;38:E2151-E2158. https://doi.org/10.1002/hed.24026
Strojan, Primož ; Vermorken, Jan B. ; Beitler, Jonathan J. ; Saba, Nabil F. ; Haigentz, Missak ; Bossi, Paolo ; Worden, Francis P. ; Langendijk, Johannes A. ; Eisbruch, Avraham ; Mendenhall, William M. ; Lee, Anne W M ; Harrison, Louis B. ; Bradford, Carol R. ; Smee, Robert ; Silver, Carl E. ; Rinaldo, Alessandra ; Ferlito, Alfio. / Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer : A systematic review. In: Head and Neck. 2016 ; Vol. 38. pp. E2151-E2158.
@article{f0017bd4d52c4934890d45d39067143a,
title = "Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review",
abstract = "Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.",
keywords = "cisplatin, concurrent chemoradiotherapy, cumulative dose, outcome, radiotherapy",
author = "Primož Strojan and Vermorken, {Jan B.} and Beitler, {Jonathan J.} and Saba, {Nabil F.} and Missak Haigentz and Paolo Bossi and Worden, {Francis P.} and Langendijk, {Johannes A.} and Avraham Eisbruch and Mendenhall, {William M.} and Lee, {Anne W M} and Harrison, {Louis B.} and Bradford, {Carol R.} and Robert Smee and Silver, {Carl E.} and Alessandra Rinaldo and Alfio Ferlito",
year = "2016",
month = "4",
day = "1",
doi = "10.1002/hed.24026",
language = "English (US)",
volume = "38",
pages = "E2151--E2158",
journal = "Head and Neck",
issn = "1043-3074",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer

T2 - A systematic review

AU - Strojan, Primož

AU - Vermorken, Jan B.

AU - Beitler, Jonathan J.

AU - Saba, Nabil F.

AU - Haigentz, Missak

AU - Bossi, Paolo

AU - Worden, Francis P.

AU - Langendijk, Johannes A.

AU - Eisbruch, Avraham

AU - Mendenhall, William M.

AU - Lee, Anne W M

AU - Harrison, Louis B.

AU - Bradford, Carol R.

AU - Smee, Robert

AU - Silver, Carl E.

AU - Rinaldo, Alessandra

AU - Ferlito, Alfio

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

AB - Background The optimal cumulative dose and timing of cisplatin administration in various concurrent chemoradiotherapy protocols for nonmetastatic head and neck squamous cell carcinoma (HNSCC) has not been determined. Methods The absolute survival benefit at 5 years of concurrent chemoradiotherapy protocols versus radiotherapy alone observed in prospective randomized trials reporting on the use of cisplatin monochemotherapy for nonnasopharyngeal HNSCC was extracted. In the case of nonrandomized studies, the outcome results at 2 years were compared between groups of patients receiving different cumulative cisplatin doses. Results Eleven randomized trials and 7 nonrandomized studies were identified. In 6 definitive radiotherapy phase III trials, a statistically significant association (p =.027) between cumulative cisplatin dose, independent of the schedule, and overall survival benefit was observed for higher doses. Conclusion Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival.

KW - cisplatin

KW - concurrent chemoradiotherapy

KW - cumulative dose

KW - outcome

KW - radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84973472579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973472579&partnerID=8YFLogxK

U2 - 10.1002/hed.24026

DO - 10.1002/hed.24026

M3 - Review article

VL - 38

SP - E2151-E2158

JO - Head and Neck

JF - Head and Neck

SN - 1043-3074

ER -